Mellor R, Kearnes M, Lancaster K, McLauchlan L, Ritter A. Established tables and emergent huddles: exploring the processes of participation associated with the policy changes to opioid pharmacotherapy treatment in Australia in the context of COVID-19. Contemp Drug Probl. 2022 Sep 8;49(4):385-404. doi: 10.1177/00914509221123001
Delacretaz A, Lagares Santos P, Saigi Morgui N, Vandenberghe F, Glatard A, Gholam-Rezaee M, von Gunten A, Conus P, Eap CB. Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs. Pharmacogenet Genomics. 2017 Dec 1;27(12):464-72. doi: 10.1097/FPC.0000000000000313
Vandenberghe F, Saigi-Morgui N, Delacretaz A, Quteineh L, Crettol S, Ansermot N, Gholam-Rezaee M, von Gunten A, Conus P, Eap CB. Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers. Pharmacogenet Genomics. 2016 Dec;26(12):547-57. doi: 10.1097/FPC.0000000000000249
Saigi-Morgui N, Vandenberghe F, Delacretaz A, Quteineh L, Gholamrezaee M, Aubry JM, von Gunten A, Kutalik Z, Conus P, Eap CB. Association of genetic risk scores with body mass index in Swiss psychiatric cohorts. Pharmacogenet Genomics. 2016 May;26(5):208-17. doi: 10.1097/FPC.0000000000000210
Quteineh L, Vandenberghe F, Saigi Morgui N, Delacretaz A, Choong E, Gholam-Rezaee M, Magistretti P, Bondolfi G, von Gunten A, Preisig M, Castelao E, Vollenweider P, Waeber G, Bochud M, Kutalik Z, Conus P, Eap CB. Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments. Pharmacogenet Genomics. 2015 May;25(5):246-58. doi: 10.1097/FPC.0000000000000131
Cobos A, Sánchez P, Aguado J, Carrasco JL. Methodological quality in pharmacogenetic studies with binary assessment of treatment response: a review. Pharmacogenet Genomics. 2011 May;21(5):243-50.
Hauber B, Candrilli S, Snyder EH, McBurney CR. Validation of a model to assess long-term disease progression in Alzheimer's disease patients treated with rivastigmine. Neurobiol Aging. 2004 Jan 1;25:S136.